Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 8.30
SGYP's Cash-to-Debt is ranked higher than
51% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. SGYP: 8.30 )
Ranked among companies with meaningful Cash-to-Debt only.
SGYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 8.3
Equity-to-Asset 0.63
SGYP's Equity-to-Asset is ranked lower than
99.99% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SGYP: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
SGYP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.63  Med: 0.63 Max: 0.63
Current: 0.63
Piotroski F-Score: 4
Altman Z-Score: 0.18
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -184144.90
SGYP's Operating Margin % is ranked lower than
99.99% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. SGYP: -184144.90 )
Ranked among companies with meaningful Operating Margin % only.
SGYP' s Operating Margin % Range Over the Past 10 Years
Min: -184144.9  Med: 0 Max: 0
Current: -184144.9
-184144.9
0
Net Margin % -207418.37
SGYP's Net Margin % is ranked lower than
99.99% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. SGYP: -207418.37 )
Ranked among companies with meaningful Net Margin % only.
SGYP' s Net Margin % Range Over the Past 10 Years
Min: -207418.37  Med: 0 Max: 0
Current: -207418.37
-207418.37
0
ROE % -522.53
SGYP's ROE % is ranked lower than
100% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SGYP: -522.53 )
Ranked among companies with meaningful ROE % only.
SGYP' s ROE % Range Over the Past 10 Years
Min: -899.32  Med: -319.1 Max: -154.96
Current: -522.53
-899.32
-154.96
ROA % -169.15
SGYP's ROA % is ranked lower than
97% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SGYP: -169.15 )
Ranked among companies with meaningful ROA % only.
SGYP' s ROA % Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -169.15
-6858.53
-69.97
ROC (Joel Greenblatt) % -29545.19
SGYP's ROC (Joel Greenblatt) % is ranked lower than
98% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. SGYP: -29545.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGYP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -423053.33  Med: -74545.45 Max: -15317.3
Current: -29545.19
-423053.33
-15317.3
3-Year EBITDA Growth Rate 6.50
SGYP's 3-Year EBITDA Growth Rate is ranked lower than
55% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. SGYP: 6.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGYP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 21.55 Max: 131.7
Current: 6.5
0
131.7
3-Year EPS without NRI Growth Rate 18.30
SGYP's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SGYP: 18.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGYP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 24.6 Max: 122.4
Current: 18.3
0
122.4
GuruFocus has detected 4 Warning Signs with Synergy Pharmaceuticals Inc $SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGYP's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SGYP Guru Trades in Q2 2016

John Paulson 27,756,668 sh (+150.29%)
Paul Tudor Jones 34,385 sh (-28.60%)
» More
Q3 2016

SGYP Guru Trades in Q3 2016

John Paulson 24,228,655 sh (-12.71%)
Paul Tudor Jones 18,144 sh (-47.23%)
» More
Q4 2016

SGYP Guru Trades in Q4 2016

Paul Tudor Jones 18,376 sh (+1.28%)
John Paulson 24,088,655 sh (-0.58%)
» More
Q1 2017

SGYP Guru Trades in Q1 2017

Louis Moore Bacon 225,000 sh (New)
Jim Simons 56,534 sh (New)
John Paulson 24,088,655 sh (unchged)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:INNL, OTCPK:TWMJF, NAS:HRTX, OTCPK:NPPNY, NYSE:LCI, OTCPK:KHTRF, NAS:AMPH, OTCPK:ACBFF, NAS:DEPO, NAS:MNTA, NAS:IPXL, NYSE:DPLO, OTCPK:APHQF, NAS:FLXN, NAS:EGRX, NAS:SCMP, NAS:SCLN, NAS:KPTI, NAS:TLGT, NAS:ACET » details
Traded in other countries:S90.Germany,
Headquarter Location:USA
Synergy Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the development and commercialization of novel gastrointestinal (GI) therapies.

Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.

Top Ranked Articles about Synergy Pharmaceuticals Inc

What Do the Ardelyx Numbers Mean for the Company? Here's a look at the latest Ardelyx data
Ardelyx Inc. (NASDAQ:ARDX) just put out data from a phase III study of its lead development asset – tenapanor. The study was the first of two planned phase IIIs with the combined data from each expected to underpin a registration submission with the Food and Drug Administration (FDA) on completion. Read more...
John Paulson Trims Synergy Company is among many drug manufacturers in portfolio
John Paulson (Trades, Portfolio) of Paulson & Co. reduced his holdings in Synergy Pharmaceuticals (NASDAQ:SGYP) by 12.5% on Sept. 19. Read more...

Ratios

vs
industry
vs
history
PB Ratio 7.47
SGYP's PB Ratio is ranked lower than
97% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SGYP: 7.47 )
Ranked among companies with meaningful PB Ratio only.
SGYP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 28.7
Current: 7.47
0
28.7
EV-to-EBIT -3.66
SGYP's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. SGYP: -3.66 )
Ranked among companies with meaningful EV-to-EBIT only.
SGYP' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.64  Med: 0 Max: 0
Current: -3.66
-7.64
0
EV-to-EBITDA -3.66
SGYP's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. SGYP: -3.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
SGYP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.65  Med: 0 Max: 0
Current: -3.66
-7.65
0
Current Ratio 3.75
SGYP's Current Ratio is ranked higher than
57% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SGYP: 3.75 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 3.07 Max: 11.88
Current: 3.75
0.04
11.88
Quick Ratio 3.53
SGYP's Quick Ratio is ranked higher than
65% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SGYP: 3.53 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.98 Max: 11.88
Current: 3.53
0.04
11.88
Days Inventory 618.26
SGYP's Days Inventory is ranked lower than
99.99% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. SGYP: 618.26 )
Ranked among companies with meaningful Days Inventory only.
SGYP' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 618.26
Current: 618.26
0
618.26
Days Sales Outstanding 23.00
SGYP's Days Sales Outstanding is ranked lower than
99.99% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. SGYP: 23.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGYP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23
Current: 23
0
23
Days Payable 5.00
SGYP's Days Payable is ranked lower than
99.99% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. SGYP: 5.00 )
Ranked among companies with meaningful Days Payable only.
SGYP' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5
Current: 5
0
5

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -31.00
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. SGYP: -31.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -248.4  Med: -23.15 Max: -14.6
Current: -31
-248.4
-14.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.94
SGYP's Price-to-Net-Cash is ranked lower than
78% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. SGYP: 9.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGYP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 26.62 Max: 582
Current: 9.94
0
582
Price-to-Net-Current-Asset-Value 7.57
SGYP's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. SGYP: 7.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGYP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 19.65 Max: 301.5
Current: 7.57
0
301.5
Price-to-Tangible-Book 7.40
SGYP's Price-to-Tangible-Book is ranked lower than
93% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SGYP: 7.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGYP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.45  Med: 19.12 Max: 597.69
Current: 7.4
4.45
597.69
Earnings Yield (Greenblatt) % -27.39
SGYP's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SGYP: -27.39 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGYP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -27.39  Med: 0 Max: 680.5
Current: -27.39
-27.39
680.5

More Statistics

Revenue (TTM) (Mil) $0.10
EPS (TTM) $ -1.07
Beta1.34
Short Percentage of Float27.17%
52-Week Range $3.35 - 7.15
Shares Outstanding (Mil)224.95

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 28 134 235
EPS ($) -0.79 -0.34 -0.11
EPS without NRI ($) -0.79 -0.34 -0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
What Do the Ardelyx Numbers Mean for the Company? May 15 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for P Mar 31 2017 
John Paulson Trims Synergy Sep 23 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
Allergan's Irritable Bowel Drug Viberzi Approved in Canada May 17 2017
What Do the Ardelyx Numbers Mean for the Company? May 15 2017
Synergy Pharmaceuticals and Durect Corporation Both Sail Higher on Trader Optimism May 15 2017
Synergy Pharma reports 1Q loss May 10 2017
Synergy Pharmaceuticals Reports First Quarter 2017 Financial Results and Business Update May 10 2017
Synergy Scores Again: Trulance Product Meets Phase 3 Endpoints In Second Indication May 09 2017
Synergy Pharmaceuticals to Present Positive TRULANCE™ (Plecanatide) Phase 3 Data at Digestive... May 09 2017
Synergy Pharmaceuticals to Present TRULANCE™ (Plecanatide) Phase 3 Data at Digestive Disease Week... May 07 2017
Synergy Presents New Insights at Digestive Disease Week (DDW) Examining Patient and Physician... May 07 2017
Synergy Pharmaceuticals to Highlight New Data for TRULANCE™ (Plecanatide) at Digestive Disease... May 01 2017
Synergy Pharmaceuticals to Present at the 42nd Annual Deutsche Bank Healthcare Conference Apr 24 2017
Synergy Pharmaceuticals Appoints Gary G. Gemignani as Chief Financial Officer Apr 17 2017
Biotech Movers: Synergy, Biogen, Insys Apr 13 2017
Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents Apr 12 2017
Synergy Pharmaceuticals Announces Issuance of Three New Patents Expected to Extend TRULANCE™... Apr 12 2017
[$$] Overheard Apr 06 2017
Drug Company's New Poop Emojis Make a Splash Apr 06 2017
Trevena, Synergy Lead Biotech Movers Apr 06 2017
Synergy Pharmaceuticals Launches the Poop Troop, the First Emoji Keyboard Designed to Support... Apr 06 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Synergy Pharmaceuticals Inc. for... Mar 30 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)